Paul Grint, M.D., Chief Medical Officer, joined IDEC in January 2001. Formerly of Schering-Plough Research Institute (SPRI), he is responsible for overseeing all clinical R&D activities in support of IDEC’s products under development. At SPRI in New Jersey for the past eight years, Dr. Grint was Vice President of Clinical Immunology and Biotechnology. In addition, he was chairman of the Biotechnology Therapy Team and an Honorary Lecturer in the Department of Virology at St. Bartholomew’s Hospital in London.
While at SPRI, Dr. Grint oversaw development of a broad-based product line and helped stimulate new business development through his involvement in licensing pharmaceutical compounds across key business areas. Prior to becoming Vice President of Clinical Immunology and Biotechnology, Dr. Grint held a number of positions of increasing responsibility at SPRI, including: executive director of the clinical data management re-engineering project, senior director, distinguished clinical research physician and director of clinical research in the Anti-Infectives Department. He received his medical degree at University of London, St. Bartholomew’s Hospital Medical College, London and is a Fellow of the Royal College of Pathologists.